Sabine Brookman-May: Are pre-treatment biopsies the way to go in mUC?
Sabine Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X about a recent paper by Niklas Klümper et al. published in Nature Reviews Urology.
“Are pre-treatment biopsies the way to go in mUC?
- Response prediction to immunotherapy, anti-NECTIN4 ADC enfortumab vedotin, FGFR inhibitor erdafitinib
- Identification of druggable alterations and treatment selection.”
“Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.”
Authors: Niklas Klümper, Alexander Cox, Gottfrid Sjödahl, Florian Roghmann, Viktor Grünwald, Bishoy Faltas, Michael Hölzel, Markus Eckstein.
More posts featuring Sabine Brookman-May.
Sabine D. Brookman-May is the Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences. Previously, she was the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson.
She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023